New combination sits at the center of this dementia and brain health question.
A new generation of combination pills and long-acting injectables for HIV prevention is now outperforming traditional daily PrEP, offering higher efficacy, simpler dosing, and in some cases, protection against both HIV and unintended pregnancy in a single tablet. The most striking development came in June 2025, when the FDA approved lenacapavir, sold under the brand name Yeztugo by Gilead Sciences, as the first twice-yearly injectable for HIV pre-exposure prophylaxis. In its pivotal clinical trial among cisgender women in South Africa and Uganda, lenacapavir achieved something daily PrEP never has: zero HIV infections, translating to 100% efficacy. These breakthroughs matter well beyond infectious disease clinics.
For the millions of older adults managing complex medication regimens, including those living with or at risk for cognitive decline, reducing pill burden is not a minor convenience. It can be the difference between consistent protection and dangerous gaps in adherence. And for caregivers coordinating care for someone with dementia who also faces HIV risk, a twice-yearly injection or a once-weekly pill represents a fundamentally different calculus than remembering a daily tablet. This article examines the specific combination approaches now reshaping HIV prevention and treatment, from lenacapavir’s landmark trial results to the dual prevention pill combining HIV and pregnancy protection, and what each of these advances means for people navigating complex health needs.
Table of Contents
- Why Are New Combination Pills for HIV Prevention Working Better Than Daily PrEP Alone?
- What Did the Landmark Lenacapavir Trials Actually Show?
- How a Once-Weekly HIV Pill Could Change Treatment for People Managing Multiple Conditions
- Comparing Your Options — Injectable, Weekly Pill, or Daily Tablet
- The Global Access Problem and What It Means for Vulnerable Populations
- The Dual Prevention Pill — Addressing HIV and Reproductive Health Together
- What the HIV Prevention Pipeline Means for the Future of Complex Care
- Conclusion
- Frequently Asked Questions
Why Are New Combination Pills for HIV Prevention Working Better Than Daily PrEP Alone?
The short answer is that newer agents attack the virus through different mechanisms and can be delivered in ways that sidestep the biggest weakness of daily oral PrEP: human inconsistency. Traditional PrEP with Truvada (tenofovir disoproxil fumarate and emtricitabine) is highly effective when taken every day, but real-world adherence rates are considerably lower than what clinical trials achieve. Missed doses create windows of vulnerability, and certain populations, including older adults with cognitive impairment, face particular challenges with daily medication compliance. Lenacapavir works through a novel mechanism as a capsid inhibitor, interfering with the protein shell that surrounds HIV’s genetic material at multiple stages of the viral life cycle. In the PURPOSE 2 trial, which enrolled 2,179 men and gender-diverse participants, only two HIV infections occurred among those receiving lenacapavir, representing approximately 99.9% protection.
The drug proved 89% more effective than daily oral Truvada and showed 96% lower HIV incidence compared to estimated background rates. By comparison, daily oral PrEP’s effectiveness in real-world settings often falls well below its clinical trial performance, precisely because people struggle to take a pill every single day. The critical difference is not just pharmacology but delivery. A twice-yearly injection eliminates 363 days of potential non-adherence per year. For caregivers managing medications for someone with early-stage dementia or mild cognitive impairment, this shift from daily vigilance to biannual clinic visits is transformative.
What Did the Landmark Lenacapavir Trials Actually Show?
The evidence base for lenacapavir rests on two large, well-designed trials that produced results unprecedented in HIV prevention research. The PURPOSE 1 trial enrolled 2,134 cisgender women across study sites in South Africa and Uganda. Among participants receiving lenacapavir injections every six months, researchers observed zero HIV infections over the study period, against a background incidence rate of 2.41 per 100 person-years. That 100% efficacy figure is not a statistical projection or a best-case scenario. It is the observed outcome. PURPOSE 2 expanded the evidence to men who have sex with men, transgender women, transgender men, and gender non-binary individuals.
The trial enrolled 2,179 participants and recorded just two HIV infections in the lenacapavir group. The World Health Organization subsequently recommended lenacapavir as a PrEP option based on these findings, and the CDC issued clinical recommendations for its use. However, these results come with important caveats that clinicians and patients should understand. The U.S. list price for Yeztugo is $28,218 per year, which creates a significant access barrier even with insurance coverage. For older adults on fixed incomes or those navigating Medicare Part D coverage gaps, this cost may be prohibitive without manufacturer assistance programs. Additionally, while the trial populations were diverse in terms of gender identity and geography, the studies did not specifically enroll large numbers of older adults or people with cognitive impairment, so the practical considerations of administering injections to these populations still need real-world validation.
How a Once-Weekly HIV Pill Could Change Treatment for People Managing Multiple Conditions
Beyond prevention, combination approaches are also reshaping HIV treatment itself. Merck and Gilead are co-developing a once-weekly oral pill combining islatravir (2 mg) and lenacapavir (300 mg), which would be the first oral HIV treatment that does not require daily dosing. Phase 2 data presented at the European AIDS Conference in 2025 showed 94% viral suppression at 48 weeks among people who switched from daily Biktarvy, matching Biktarvy’s own suppression rate. At 96 weeks of follow-up, full viral suppression was maintained with zero cases of virologic failure or drug resistance. For someone living with HIV who is also experiencing early cognitive decline, reducing their antiretroviral regimen from a daily pill to a weekly one could meaningfully improve adherence and outcomes.
Caregivers who manage weekly pill organizers know that seven-day compliance is far more achievable than daily compliance, particularly when the person receiving care has difficulty remembering whether they have already taken their medication on a given day. Two Phase 3 studies of the fixed-dose combination tablet are now underway. It is worth noting a limitation here. Merck discontinued its development of once-monthly islatravir for PrEP, meaning this particular combination is currently being studied only for treatment of people already living with HIV, not for prevention. People should not confuse the once-weekly treatment pill with a prevention option.
Comparing Your Options — Injectable, Weekly Pill, or Daily Tablet
The expanding range of HIV prevention and treatment options means that the right choice depends heavily on individual circumstances, and there are genuine tradeoffs to consider. Lenacapavir as a twice-yearly injection offers the highest efficacy and the lowest adherence burden, but it requires clinic visits for administration and carries the highest annual cost at $28,218 in the United States. Daily oral PrEP with Truvada is available as a generic, making it far more affordable, but its real-world effectiveness depends entirely on consistent daily use. Gilead’s investigational single-tablet regimen combining bictegravir (75 mg) and lenacapavir (50 mg) met its primary endpoint in the Phase 3 ARTISTRY-2 trial for HIV treatment.
Among virologically suppressed adults who switched from Biktarvy to this combination, 1.3% had detectable viral loads at Week 48 compared to 1.0% on Biktarvy, demonstrating non-inferiority. The combination was generally well tolerated with no new safety concerns, and Gilead plans to file with regulatory authorities based on these results. While this is a treatment option rather than prevention, it illustrates how combination strategies are consolidating multiple mechanisms into simpler regimens. For older adults and their caregivers, the decision framework should weigh several factors: cognitive capacity for daily medication management, frequency of existing healthcare appointments where an injection could be administered, insurance coverage and out-of-pocket costs, and whether the individual needs prevention or treatment. A geriatrician or HIV specialist can help navigate these considerations, and it is worth raising the conversation proactively rather than waiting.
The Global Access Problem and What It Means for Vulnerable Populations
One of the most significant limitations of these breakthrough therapies is the gap between clinical promise and actual availability. While lenacapavir achieved extraordinary results in trials conducted largely in sub-Saharan Africa, its U.S. list price of $28,218 per year puts it out of reach for many of the people who need it most. This pricing tension is not unique to HIV prevention, but it is particularly stark given that the populations at highest risk are often those with the fewest financial resources. In September 2025, the Gates Foundation and Unitaid announced partnerships with generic manufacturers to provide lenacapavir for PrEP at $40 per person per year in up to 120 countries, with availability projected to begin in 2027.
That 700-fold price difference between the U.S. list price and the global access price underscores the structural inequities in pharmaceutical markets. For people in the United States, particularly older adults on fixed incomes who may not qualify for Medicaid but find commercial insurance premiums and copays burdensome, the path to affordable access remains unclear. Caregivers and advocates should be aware that patient assistance programs, state AIDS Drug Assistance Programs, and the federal 340B drug pricing program may provide avenues to reduced-cost access. However, navigating these systems requires time, paperwork, and often a knowledgeable case manager, resources that are themselves in short supply for people simultaneously managing cognitive decline or dementia caregiving.
The Dual Prevention Pill — Addressing HIV and Reproductive Health Together
A different kind of combination approach is targeting the intersection of HIV prevention and family planning. Developed by Viatris, the Dual Prevention Pill combines oral PrEP (tenofovir disoproxil fumarate and emtricitabine) with oral contraception (ethinyl estradiol and levonorgestrel) in a single daily tablet. The pill has successfully demonstrated bioequivalence, meaning its active ingredients are absorbed at the same rate and extent as when taken separately.
Viatris submitted the product for WHO pre-qualification in 2025, with approval anticipated in 2026. This combination specifically targets East and Southern Africa, where 68% of new HIV infections occur among women of reproductive age, with an estimated potential market of 251,000 to 1.25 million women across 15 African countries. While this product may seem distant from a dementia care context, it reflects a broader principle that applies universally: combining health interventions into fewer pills improves adherence and outcomes. For older women who may still need hormonal therapy alongside other preventive medications, the concept of consolidation is equally relevant.
What the HIV Prevention Pipeline Means for the Future of Complex Care
The advances in HIV combination therapies signal a broader shift in how medicine approaches chronic disease management, one that has direct implications for dementia care and aging. The principle that fewer doses, longer-acting formulations, and combination regimens produce better real-world outcomes is not limited to infectious disease. Alzheimer’s researchers and geriatricians are watching these delivery innovations closely, because the adherence challenges that plague HIV prevention are the same ones that undermine dementia treatment, hypertension management, and diabetes care in older adults.
With two Phase 3 trials of the once-weekly islatravir and lenacapavir combination now underway, and Gilead preparing regulatory filings for its bictegravir and lenacapavir single-tablet regimen, the pipeline over the next two to three years is likely to deliver multiple new options that reduce the daily burden of HIV management. For clinicians, caregivers, and patients navigating the intersection of HIV risk and cognitive health, staying informed about these options is not optional. It is part of providing competent, comprehensive care.
Conclusion
The landscape of HIV prevention and treatment has shifted decisively away from the daily-pill-only model that defined the first decade of PrEP. Lenacapavir’s FDA approval as a twice-yearly injectable with near-perfect efficacy, the emergence of once-weekly oral treatment combinations maintaining viral suppression for 96 weeks without resistance, and the development of dual-purpose pills addressing both HIV and reproductive health represent a genuine leap forward. Each of these approaches addresses the fundamental problem that has always limited PrEP’s real-world impact: the difficulty of taking a pill every single day, a challenge that is magnified for anyone dealing with cognitive impairment.
For caregivers and families managing dementia alongside other health concerns, the practical takeaway is clear. Discuss these newer options with healthcare providers now, rather than waiting for them to be offered. Ask specifically about lenacapavir eligibility, insurance coverage, and patient assistance programs. And recognize that the move toward longer-acting, combination-based approaches in HIV care reflects a principle that applies across all of chronic disease management: simpler regimens save lives, especially when memory and executive function are compromised.
Frequently Asked Questions
Is the twice-yearly lenacapavir injection available now in the United States?
Yes. The FDA approved lenacapavir (brand name Yeztugo) for HIV pre-exposure prophylaxis on June 18, 2025. It is available by prescription, though the U.S. list price of $28,218 per year means that insurance coverage and patient assistance programs are important factors in actual access.
Can someone with dementia receive the lenacapavir injection for HIV prevention?
There is no medical contraindication based on dementia diagnosis alone, but the decision should involve the person’s healthcare team and legal decision-maker. The twice-yearly injection schedule actually makes it easier to administer than daily oral PrEP for someone with cognitive impairment, since it can be given during routine clinic visits.
Is the once-weekly HIV pill available yet?
Not yet. The once-weekly combination of islatravir and lenacapavir is currently in Phase 3 clinical trials for HIV treatment, not prevention. It has shown promising results through 96 weeks of Phase 2 data, but regulatory approval is still likely several years away.
How does the cost of lenacapavir compare to daily oral PrEP?
Lenacapavir’s U.S. list price is $28,218 per year, while generic Truvada for daily PrEP can cost as little as $0 to $60 per month through various programs. However, global access pricing through the Gates Foundation and Unitaid partnership aims to make lenacapavir available for $40 per person per year in up to 120 countries by 2027.
Does the Dual Prevention Pill work for older women?
The Dual Prevention Pill, which combines HIV PrEP with oral contraception, is specifically designed for women of reproductive age. It is not intended for postmenopausal women, who would not need the contraceptive component. Older women seeking HIV prevention should discuss other PrEP options, including lenacapavir, with their provider.
Are there side effects unique to the combination approaches compared to standard PrEP?
The Phase 3 ARTISTRY-2 trial of bictegravir plus lenacapavir reported the combination was generally well tolerated with no new safety concerns compared to Biktarvy alone. Lenacapavir as an injectable can cause injection site reactions. Each combination has its own safety profile, and patients should review specific risks with their prescribing clinician.
You Might Also Like
- Why Doctors Are Testing a Diabetes Drug for Kidney Stone Prevention
- New Injectable Cholesterol Drug Works After Just One Dose a Year
- Why Your Heartburn Medication May Be Contributing to Your Depression
For more, see Alzheimer’s Association — medical tests.
